What is Rayonier Advanced's latest dividend and current dividend yield?

What is Rayonier Advanced's gross profit margin?

What is the revenue and EPS growth rate for Rayonier Advanced year over year?

What were the key takeaways from Rayonier Advanced's earnings call?

What does Rayonier Advanced do and what are its main business segments?

What guidance did Rayonier Advanced's management provide for the next earnings period?

What is the market's earnings forecast for Rayonier Advanced next quarter?

What were the key takeaways from Rayonier Advanced’s earnings call?

- **2026 Free Cash Flow Target**: Achieve positive free cash flow after 2025 negative USD 88M result.
- **Specialties Pricing Power**: 18% price increase locked in for 85% of business; remaining 15% will require higher increases.
- **New Product Growth**: Foldable freezer board and oil-and-grease board driving Paperboard EBITDA improvement.
- **Debt Refi Opportunity**: CFO highlights plans to reduce interest expense through capital structure optimization.

**【CEO Opening Remarks】**
- RYAM reported negative free cash flow of USD 88 million in 2025, with a critical focus on achieving positive free cash flow in 2026.
- Key priorities include: 
  1. Delivering positive free cash flow in 2026.
  2. Asserting leadership in Cellulose Specialties with an 18% average price increase (excluding 15% of business still under negotiation).
  3. Improving EBITDA across all businesses through new product commercialization and operational efficiency.
- 2026 EBITDA expected to surpass 2025 levels, with Q1 2026 EBITDA near-zero due to leadership initiative ramp-up.

**【CFO Financial Commentary】**
- CFO Marcus Moeltner emphasized the importance of refi to address high-cost debt and reduce interest expenses.
- 2026 financial strategy includes: 
  - Leveraging new product introductions (e.g., oil-and-grease board, foldable freezer board) to drive Paperboard segment growth.
  - Optimizing production mix to maximize contribution margins across specialties, commodities, and biomaterials.

**【Q&A Highlights】**
- **Cellulose Specialties Pricing**: Remaining 15% of business will only be placed at price increases significantly above 18%, with antidumping/countervailing duty cases expected to resolve in Q2 2026.
- **Biomaterials Strategy**: Tartas plant optimization is enabling increased ethanol production for BioNova JV, while reducing reliance on specialty volume.
- **Paperboard Segment**: Sequential Q4 volume and price growth driven by new freezer board product and improved plant productivity.
- **Competitive Dynamics**: U.S. specialty producers are exiting due to subsidized imports, creating opportunity for RYAM to capture domestic market share.


Rayonier Advanced Materials Inc.(RYAM)-20260304-2025 Q4 Earnings call transcript

- **2025 EBITDA Guidance**: $135M-$140M (down from $150M-$160M) due to strategic downtime in non-core assets.
- **Tariff Mitigation**: 10% fluff tariff countered by new dissolving wood pulp fluff product in development.
- **Temiscaming Turnaround**: 2026 initiatives target $30M EBITDA improvement via cost cuts, efficiency gains, and new products.
- **Biomaterials Growth**: AGE project ($500M, 12x ROI) and BioNova ethanol ($64M, 19x ROI) driving 2026-2027 EBITDA expansion.
- **Pricing Reset**: 4-6%+ 2026 price increase to recapture 35% inflation differential since 2014.

**【CEO Summary Section】**
- **Updated 2025 Guidance**: Adjusted EBITDA refined to $135M-$140M (from $150M-$160M) due to strategic downtime in non-core Paperboard and high-yield pulp lines. 
- **Tariff Developments**: 0% tariffs on Cellulose Specialties and dissolving wood pulp into China; 10% fluff tariff mitigation via new dissolving wood pulp fluff product in development. U.S. ITC affirmative injury determination for Brazilian and Norwegian dissolving pulp imports.
- **Operational Stabilization**: French strikes at Tartas resolved; key technical roles filled at Temiscaming and Tartas. Jesup and Fernandina performing to expectations.
- **Temiscaming Turnaround**: 2025 EBITDA loss of $14M vs. historical $30M; 4 initiatives to restore profitability: $10M cost reduction, $10M OEE improvement, $10M new product EBITDA, and strategic divestiture exploration.
- **2027 EBITDA Plan**: Target $300M+ EBITDA through pricing reset, $30M cost reduction, specialty mix shift, and biomaterials growth. 2026 pricing reset targeting 4-6%+ increase to recapture 35% inflation differential since 2014.

**【CFO Financial Commentary】**
- **Q3 2025 Results**: Revenue $353M (-13% YoY); Adjusted EBITDA $42M (-17% YoY). Cellulose Specialties EBITDA $66M (+2% YoY), margins 32% vs. 28% prior year. Paperboard EBITDA $1M (-90% YoY); High-Yield Pulp EBITDA -$9M (-100% YoY). 
- **Segment Performance**: Cellulose Commodities loss narrowed to -$3M (from -$10M); Biomaterials EBITDA $1M (down 75% YoY). 
- **Liquidity**: $140M total liquidity; 2025 free cash flow expected $25M-$30M. $40M green debt available for biomaterials projects.

**【Q&A Key Highlights】**
- **Temiscaming Sale Milestones**: USMCA renewal (July 2026) and positive EBITDA/cash flow required for divestiture. 2026 milestones: $10M cost savings, $10M OEE improvement, and new product commercialization.
- **Refinancing Strategy**: 2026 debt refinancing contingent on 2025 EBITDA recovery. Target leverage below 4x to regain balance sheet flexibility.
- **Pricing Reset Impact**: 1% price increase generates $8M-$9M EBITDA; targeting 4-6%+ increase to recapture $300M inflation differential. 
- **AGE Project Progress**: $500M renewable energy project with 12x ROI on $46M equity. FID pending financing resolution. 
- **Fluff Product Development**: Dissolving wood pulp fluff product in testing; cost reduction efforts underway to justify tariff avoidance.


Rayonier Advanced Materials Inc.(RYAM)-20251105-2025 Q3 Earnings call transcript

- **2025 Challenges**: $59M EBITDA headwinds from tariffs, FX, and operational issues, with Q2 as trough quarter.
- **Growth Ambition**: Target $308M EBITDA by 2027 via cost cuts, market share gains, and biomaterials (e.g., AGE project with 10-12x ROI).
- **Financial Update**: Q2 EBITDA $28M (-58% YoY), 2025 guidance revised to $150-160M, with H2 recovery.
- **Strategic Moves**: Biomaterials projects to generate $39M EBITDA by 2027; tariffs boost U.S. market share and pricing power.

**【CEO Summary Section】**
- **Headwinds and Recovery**: Faced $59M EBITDA headwinds in 2025 due to tariffs ($21M), FX losses ($8M), operational disruptions ($18M), environmental charges ($12M), and non-core segment softness. Q2 2025 is the trough quarter, with normalization expected in H2 2025.
- **EBITDA Growth Strategy**: Aims to nearly double EBITDA to $308M by 2027, driven by cost reductions ($30M+), capturing market share in cellulose specialties, and biomaterials projects (e.g., AGE at Jesup with 10-12x ROI).
- **Biomaterials Initiative**: Bioethanol project at Tartas ($5M equity) generates $8-10M EBITDA annually. Future projects include bioelectricity, prebiotics, and SAF, targeting $39M EBITDA by 2027.

**【CFO Financial Commentary】**
- **Q2 2025 Results**: Revenue $340M (-19% YoY), EBITDA $28M (-58% YoY). CS segment EBITDA $29M (-42% YoY) due to tariffs and labor strikes. Paperboard and high-yield pulp segments underperformed due to soft demand.
- **Guidance Update**: 2025 EBITDA revised to $150-160M (vs. $215-235M), with H2 EBITDA $105-115M. Free cash flow expected to be negative $10-25M for the year.

**【Q&A Highlights】**
- **Product Approval Timeline**: New dissolving wood pulp fluff product trials in China; commercialization expected in 2026.
- **Cost Reduction Execution**: $24M capital spent in 2025, with $30M savings realized in 2026. Temiscaming turnaround initiatives (freezer board, oil/grease-resistant board) to commercialize in 2026.
- **Capital Allocation**: Prioritize high-return biomaterials projects (e.g., AGE) and debt repayment. Share buybacks considered if projects dry up.
- **Tariff Impact**: 15% EU and 50% Brazil tariffs enhance competitive advantage, supporting U.S. market share and pricing strategy.

Rayonier Advanced Materials Inc. (RYAM) Q2 2025 Earnings Conference Call Transcript

- **Q1 2025 Results Miss Expectations:** Revenue down 8%, EBITDA down 67% due to Chinese tariffs and operational challenges.
- **Tariff Mitigation Progress:** Shifting fluff pulp to non-China markets, exploring dissolving wood pulp opportunities in China.
- **Revised Guidance:** 2025 EBITDA $175-185M (vs. prior $220M), free cash flow $5-15M, reflecting $20M tariff impact.
- **Financial Strength:** Liquidity $272M, net debt $624M, leverage 2.9x, maintaining covenant compliance.
- **Key Risk:** High-yield pulp segment EBITDA expected to remain negative due to market oversupply.

**【CEO Performance Overview】**
- Q1 2025 revenue declined 8% YoY to $344 million, with adjusted EBITDA down 67% to $47 million, primarily due to tariffs on U.S. cellulose commodities in China.
- Key challenges included customer destocking, operational setbacks (e.g., Jesup plant cold weather issues), higher energy costs (+$3 million), and $12 million non-cash environmental reserves.
- Full-year 2025 guidance revised to $175-185 million EBITDA (vs. prior $220 million midpoint) and $5-15 million free cash flow, reflecting $20 million tariff impact and $15 million Q1 operational underperformance.

**【CFO Financial Breakdown】**
- **Cellulose Specialty (CS):** Q1 net sales $201 million (-2% YoY), operating income $31 million (-21%), EBITDA margin 23% (vs. 27% prior).
- **Cellulose Commodities (CC):** Net sales $75 million (-20%), operating loss $13 million (improved $6 million YoY) due to reduced negative margin grades.
- **Biomaterials:** Steady at $7 million sales, $2 million operating income, 29% EBITDA margin.
- **Paperboard:** Sales $49 million (-8%), operating loss $2 million (vs. $10 million profit prior), driven by European imports and price declines.
- **High Yield Pulp:** Sales $31 million (-10%), operating loss $7 million (worsened $2 million YoY).
- **Liquidity:** $272 million (cash $130M, ABL $131M), net debt $624 million, leverage 2.9x covenant EBITDA.

**【Tariff Mitigation & Strategy】**
- **Customer Advocacy:** Engaging directly with Chinese authorities to clarify CS product tariff exemptions.
- **Market Diversification:** Shifting fluff pulp sales to India, Africa, Middle East; exploring dissolving wood pulp (viscose) opportunities in China.
- **Operational Adjustments:** Idling one high-yield pulp line for 11 weeks to reduce oversupply; resuming CC production of non-tariff-affected grades.
- **Strategic Pauses:** Delaying debt reduction and non-core CC investments; maintaining biomaterials strategy despite tariffs.

**【Q&A Highlights】**
- **Tariff Impact on CS:** Orders resumed post-April pause, but customers accelerating destocking; 2025 CS EBITDA guided to $237-245 million (midpoint -6% YoY).
- **Paperboard Pricing:** 5% YoY decline expected due to new SAFI capacity, but long-term demand growth driven by sustainable packaging trends.
- **Liquidity Confidence:** CFO emphasizes $272M liquidity, disciplined cash management, and ability to meet debt covenant compliance.
- **Bioethanol Expansion:** Fernandina plant permit challenges ongoing, but confident in project benefits; Tartas plant operational issues resolved post-Q1.

Rayonier Advanced Materials (RYAM)-7 May 25-2025 Q1 Earnings call transcript

- **Record EBITDA Growth**: 2024 adjusted EBITDA up 60% to $222 million, driven by HPC specialty pricing and cost savings. 
- **Debt Reduction**: Net secured debt down $73 million to $625 million, leverage at 2.7x (target 2.5x). 
- **Tariff Mitigation**: 25% U.S. paperboard tariffs expected to impact $35 million EBITDA, but 30,000 metric tons of Canadian sales conversions to offset. 
- **Biomaterials Expansion**: AGE project EBITDA potential $25-$30 million/year, with full production by 2028. 
- **CS Strategy**: Value over volume in acetate, ethers demand strong in pharma/food, construction recovery possible. 


**【CEO Summary Section】**
- **2024 Financial Highlights**: Revenue of $1.63 billion (-$13 million YoY), operating income of $39 million (+$104 million YoY), adjusted EBITDA of $222 million (+$83 million YoY, 60% growth). Free cash flow reached $128 million (+$75 million YoY). Net secured debt reduced by $73 million to $625 million, with leverage at 2.7x covenant EBITDA (target 2.5x). 
- **Key Drivers**: High-purity cellulose (HPC) EBITDA grew $93 million (65% YoY) due to higher specialty pricing, volumes, and cost savings from Temiscaming suspension. Paperboard EBITDA declined $4 million due to lower prices and labor costs, while high-yield pulp EBITDA fell $4 million due to tariffs and custodial site costs. 
- **2025 Outlook**: EBITDA guidance of $215-$235 million, including 25% U.S. paperboard tariffs. Focus on value over volume in CS, biomaterials expansion, and debt reduction. 

**【CFO Financial Commentary】**
- **Segment Performance**: 
  - **HPC**: Sales $1.3 billion (-3% YoY), EBITDA $237 million (+$93 million YoY). CS volumes up 19% due to competitor closure, demand recovery, and Temiscaming suspension benefits. 
  - **Paperboard**: Sales $228 million (+$9 million YoY), EBITDA $48 million (-$4 million YoY). Higher volumes offset by tariffs and custodial costs. 
  - **High-Yield Pulp**: Sales $127 million (-7% YoY), EBITDA loss $1 million (vs. $1 million loss YoY). Pricing down 9% due to Chinese oversupply. 
- **Liquidity**: $276 million (cash $125 million, undrawn ABL $141 million). 2024 capex $108 million ($33 million strategic). 
- **Debt**: Reduced to $653 million (-$68 million YoY). Term loan net secured leverage 2.7x covenant EBITDA. 

**【Q&A Key Highlights】**
- **Capital Allocation**: 2025 capex $194 million (maintenance $85 million, strategic $109 million). Strategic capex focused on CS cost efficiency ($19 million) and biomaterials ($14 million). 
- **Tariff Mitigation**: 25% U.S. paperboard tariffs expected to impact $175 million in sales. Plan to replace 30,000 metric tons of U.S. exports with Canadian domestic sales. AGE project EBITDA potential $25-$30 million/year. 
- **CS Volumes**: Acetate destocking global, mid-single-digit demand decline. Ethers demand strong in food/pharma, construction recovery possible. 
- **Biomaterials**: 2025 EBITDA guidance $8-$10 million. AGE project FID in late 2025, full production by 2028. Bioethanol delays push $40 million EBITDA target to 2028. 


Actual											-0.39	-0.2	0.45	-0.03	-0.43	0.14	-0.21	-0.37	-0.38	-0.39	0.28	0.04	0.05	-0.25	-0.4	-0.22	-0.02	0.19	-0.12	-0.1	-0.49	-5.47	-0.07	-0.32
Forecast											-0.46	-0.3167	-0.1433	-0.1	0.3933	0.74	0.0167	-0.0967	-0.41	-0.2033	0.1	0.04	0.065	-0.12	-0.3067	-0.0733	-0.1033	-0.0967	-0.0767	-0.1867	-0.09	-0.2333	-0.07	-0.08
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+15.22%	+36.85%	+414.03%	+70.00%	-209.33%	-81.08%	-1357.48%	-282.63%	+7.32%	-91.83%	+180.00%	0.00%	-23.08%	-108.33%	-30.42%	-200.14%	+80.64%	+296.48%	-56.45%	+46.44%	-444.44%	-2244.62%	0.00%	-300.00%

Actual	--	--	--	--	--	--	--	--	--	--	410.00M	397.00M	424.00M	508.00M	465.00M	341.00M	374.00M	374.00M	352.00M	399.00M	466.00M	500.00M	467.00M	385.00M	369.00M	422.00M	388.00M	419.00M	401.00M	422.00M	356.00M	340.00M	353.00M	417.00M
Forecast	--	--	--	--	--	--	--	--	--	--	427.81M	405.43M	435.07M	454.35M	520.03M	523.07M	381.20M	375.61M	367.35M	385.70M	420.42M	436.36M	448.78M	417.63M	393.17M	410.27M	429.70M	402.17M	410.03M	416.90M	385.00M	385.50M	373.60M	364.07M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-4.16%	-2.08%	-2.54%	+11.81%	-10.58%	-34.81%	-1.89%	-0.43%	-4.18%	+3.45%	+10.84%	+14.58%	+4.06%	-7.81%	-6.15%	+2.86%	-9.70%	+4.19%	-2.20%	+1.22%	-7.53%	-11.80%	-5.51%	+14.54%

RYAM

RYAM fundamentals

RYAM Q4 2025 Earnings

Earnings Call

You can ask Aime

RYAM

RYAM fundamentals

RYAM Q4 2025 Earnings

Earnings Call

RYAM Earnings Call Summary for Q4/20259:00 AM on Mar 4, 2026

RYAM Earnings Call Summary for Q3/20259:00 AM on Nov 5, 2025

RYAM Earnings Call Summary for Q2/20259:00 AM on Aug 6, 2025

RYAM Earnings Call Summary for Q1/20259:00 AM on May 7, 2025

RYAM Earnings Call Summary for Q4/20249:00 AM on Mar 6, 2025

You can ask Aime